| Novel patterns of response under immunotherapy E Borcoman, Y Kanjanapan, S Champiat, S Kato, V Servois, R Kurzrock, ... Annals of Oncology 30 (3), 385-396, 2019 | 432 | 2019 |
| Hyperprogressive disease in early‐phase immunotherapy trials: Clinical predictors and association with immune‐related toxicities Y Kanjanapan, D Day, L Wang, H Al‐Sawaihey, E Abbas, A Namini, ... Cancer 125 (8), 1341-1349, 2019 | 143 | 2019 |
| Seamless designs: current practice and considerations for early-phase drug development in oncology BP Hobbs, PC Barata, Y Kanjanapan, CJ Paller, J Perlmutter, GR Pond, ... JNCI: Journal of the National Cancer Institute 111 (2), 118-128, 2019 | 61 | 2019 |
| Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials Y Kanjanapan, D Day, MO Butler, L Wang, AM Joshua, D Hogg, ... European Journal of Cancer 107, 1-7, 2019 | 60 | 2019 |
| Folic acid prevents and partially reverses glucocorticoid-induced hypertension in the rat Y Miao, Y Zhang, PS Lim, Y Kanjanapan, TA Mori, KD Croft, J Earl, ... American journal of hypertension 20 (3), 304-310, 2007 | 42 | 2007 |
| Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib CK Lee, D Goldstein, E Gibbs, H Joensuu, J Zalcberg, J Verweij, ... European Journal of Cancer 51 (7), 852-860, 2015 | 32 | 2015 |
| Niraparib for the treatment of ovarian cancer Y Kanjanapan, S Lheureux, AM Oza Expert opinion on pharmacotherapy 18 (6), 631-640, 2017 | 26 | 2017 |
| Prognostic significance of KIT exon 11 deletion mutation in intermediate‐risk gastrointestinal stromal tumor R Quek, M Farid, Y Kanjanapan, C Lim, IB Tan, S Kesavan, TKH Lim, ... Asia‐Pacific Journal of Clinical Oncology 13 (3), 115-124, 2017 | 17 | 2017 |
| Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil‐to‐lymphocyte ratio in patients with metastatic renal cell carcinoma D Day, Y Kanjanapan, E Kwan, D Yip, N Lawrentschuk, ID Davis, ... Internal medicine journal 46 (11), 1291-1297, 2016 | 16 | 2016 |
| Patterns of care for metastatic renal cell carcinoma in A ustralia D Day, Y Kanjanapan, E Kwan, D Yip, N Lawrentschuk, M Andrews, ... BJU international 116, 36-41, 2015 | 15 | 2015 |
| Glut-1 expression in small cervical biopsies is prognostic in cervical cancers treated with chemoradiation Y Kanjanapan, S Deb, RJ Young, M Bressel, L Mileshkin, D Rischin, ... Clinical and translational radiation oncology 2, 53-58, 2017 | 13 | 2017 |
| Considerations for cancer immunotherapy during the COVID-19 pandemic Y Kanjanapan, D Yip The Medical Journal of Australia 213 (9), 390-392. e1, 2020 | 7 | 2020 |
| Acute ischaemic stroke following cisplatin-based chemotherapy for testicular cancer Y Kanjanapan, D Gilbourd, G Pranavan BMJ Case Reports CP 13 (5), e235005, 2020 | 7 | 2020 |
| Phase II clinical and molecular trial of oral ENMD-2076 in clear cell ovarian cancer (CCOC): A study of the Princess Margaret phase II consortium. S Lheureux, JV Burnier, Q Tan, Y Kanjanapan, B Clarke, A Tinker, ... Journal of Clinical Oncology 35 (15_suppl), 5522-5522, 2017 | 7 | 2017 |
| PS-139-Liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy M Cunningham, M Iafolla, Y Kanjanapan, O Cerocchi, M Butler, L Siu, ... Journal of Hepatology 70 (1), e89, 2019 | 6 | 2019 |
| Hyperprogressive disease (HPD) in early-phase immunotherapy (IO) trials. Y Kanjanapan, D Day, L Wang, AR Hansen, AR Abdul Razak, A Spreafico, ... Journal of Clinical Oncology 36 (15_suppl), 3063-3063, 2018 | 6 | 2018 |
| Impact of prior (neo) adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer Y Kanjanapan, SW Lok, P Gibbs, R De Boer, B Yeo, S Greenberg, ... Breast cancer research and treatment 184 (1), 87-95, 2020 | 5 | 2020 |
| Survival in early phase immuno-oncology trials: development and validation of a prognostic index D Day, C Guo, Y Kanjanapan, B Tran, A Spreafico, AM Joshua, L Wang, ... JNCI Cancer Spectrum 3 (4), pkz071, 2019 | 5 | 2019 |
| Immunologic and genomic characterization of high grade serous ovarian cancer (HGSOC) in patients (pts) treated with pembrolizumab (Pembro) in the phase II INSPIRE trial. I Colombo, S Lien, C Yang, DL Clouthier, L Bonilla, S Cyriac, JL Ethier, ... Journal of Clinical Oncology 35 (15_suppl), 5581-5581, 2017 | 5 | 2017 |
| Phase II open-label randomized multi-centre study of neoadjuvant olaparib in patients (pts) with platinum sensitive (PS) relapsed high grade serous ovarian cancer (OC): The NEO … Y Kanjanapan, S Lheureux, T May, MK Wilson, M Bernardini, PA Shaw, ... Journal of Clinical Oncology 35 (15_suppl), TPS5608-TPS5608, 2017 | 3 | 2017 |
